ACM Global Central Lab Head of R&D to Present at New Dynamics of Biomarker Labs, Central Labs and ECG & Imaging Labs in London

Dr. Andrew Botham Offers Guidance for Detecting Drug-Induced Organ Toxicity Early in Clinical Trials

ROCHESTER, N.Y.--(BUSINESS WIRE)--ACM Global Central Laboratory, the central laboratory that continually defines the customer-service standard with its flexible approach, today announced that it will feature Head of R&D Dr. Andrew Botham as a speaker at this year’s New Dynamics of Biomarker Labs, Central Labs and ECG & Imaging Labs in London on February 27-28, 2013.

“DILI to DIOT: The early detection of drug-induced organ toxicity. Is your trial asking the right questions?”

Dr. Andrew Botham will present, "DILI to DIOT: The early detection of drug-induced organ toxicity. Is your trial asking the right questions?" His presentation will look at drug-induced liver injury (DILI), the primary cause for post-marketing drug withdrawal and market restriction, and explore key questions around how and why DILI is missed during clinical trials. Additionally, Dr. Botham will offer new strategies for detecting other forms of drug-induced organ toxicity.

Dr. Andrew Botham is a state-registered biomedical scientist with a master’s degree in biotechnology and a PhD in medicine. He has worked within the NHS, private pharma, as well as in academic research. As the Head of R&D at ACM Global Central Laboratory, his responsibilities focus on the identification and development of new analytical practices within ACM Global, in advising project management and business development of scientific, clinical and technical aspects of all company procedures, as well as promoting and maintaining scientific excellence throughout the company.

Botham’s presentation will be held on Thursday, Feb. 28^th at 9:00 a.m.

To meet with ACM Global Central Lab at New Dynamics of Biomarker Labs, Central Labs and ECG & Imaging Labs or for more information, please visit the website.

About ACM Global Central Lab

ACM Global Central Lab offers a flexible approach and a focus on precision to optimize the clinical study outcomes for our clients. ACM Global performs 20 million diagnostic tests each year, offering more than 1,500 individual assays spanning virtually all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics. ACM Global’s services extend to more than 60 countries, with all tests conducted and managed from central lab facilities and a seamless data management process providing a single global database.

For more information, visit www.acmgloballab.com, our Central Labs in Focus blog or call [phone].